A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
코로나19 입원 환자를 위한 중화 단일클론항체
Randomized Controlled Trial
[키워드] 1:1
95% CI
95% confidence interval
addition
Administered
adverse event
all the patients
antibody
antiviral drug
assigned
categories
category
Composite
coronavirus disease
Coronavirus disease 2019
Data and Safety Monitoring Board
death
decrease
dose
Efficacy
emergency department
end-organ
Enrollment
Frequency
futility
Glucocorticoids
grade 3
Hospitalization
hospitalizations
Hospitalized
hospitalized patient
hospitalized patients
in viral
indicated
infusion
interquartile range
intravenous infusion
LY-CoV555
matching placebo
median interval
monitoring board
monoclonal antibody
Neutralizing
Odds ratio
onset of symptom
operation
Ordinal Scale
outcome
Outpatient
outpatients
oxygen
Patient
Placebo
placebo group
Platform trial
Primary outcome
Pulmonary function
randomization
Randomly
rate ratio
receive
Remdesivir
Serious Adverse Events
Seven
seven-category ordinal scale
single intravenous infusion
speed
supplemental oxygen
supportive care
sustained
the patient
the placebo group
therapeutic agents
therapy
time-to-event analysis
Viral
Viral load
was performed
[DOI] 10.1056/NEJMoa2033130 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1056/NEJMoa2033130 PMC 바로가기 [Article Type] Randomized Controlled Trial